4-88008021-CGAGGAGGAG-CGAGGAGGAGGAG

Variant summary

Our verdict is Benign. The variant received -17 ACMG points: 0P and 17B. BP3BP6_Very_StrongBS1BS2

The NM_000297.4(PKD2):​c.305_307dupAGG​(p.Glu102dup) variant causes a disruptive inframe insertion change. The variant allele was found at a frequency of 0.00112 in 1,516,764 control chromosomes in the GnomAD database, including 11 homozygotes. Variant has been reported in ClinVar as Likely benign (★★).

Frequency

Genomes: 𝑓 0.0046 ( 9 hom., cov: 32)
Exomes 𝑓: 0.00073 ( 2 hom. )

Consequence

PKD2
NM_000297.4 disruptive_inframe_insertion

Scores

Not classified

Clinical Significance

Benign/Likely benign criteria provided, multiple submitters, no conflicts B:11

Conservation

PhyloP100: 4.02

Publications

3 publications found
Variant links:
Genes affected
PKD2 (HGNC:9009): (polycystin 2, transient receptor potential cation channel) This gene encodes a member of the polycystin protein family. The encoded protein is a multi-pass membrane protein that functions as a calcium permeable cation channel, and is involved in calcium transport and calcium signaling in renal epithelial cells. This protein interacts with polycystin 1, and they may be partners in a common signaling cascade involved in tubular morphogenesis. Mutations in this gene are associated with autosomal dominant polycystic kidney disease type 2. [provided by RefSeq, Mar 2011]
PKD2 Gene-Disease associations (from GenCC):
  • autosomal dominant polycystic kidney disease
    Inheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: Orphanet, ClinGen
  • polycystic kidney disease 2
    Inheritance: AD, AR Classification: STRONG, LIMITED Submitted by: Labcorp Genetics (formerly Invitae), Ambry Genetics, Genomics England PanelApp

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -17 ACMG points.

BP3
Nonframeshift variant in repetitive region in NM_000297.4
BP6
Variant 4-88008021-C-CGAG is Benign according to our data. Variant chr4-88008021-C-CGAG is described in ClinVar as Benign/Likely_benign. ClinVar VariationId is 193079.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BS1
Variant frequency is greater than expected in population afr. GnomAd4 allele frequency = 0.00463 (698/150616) while in subpopulation AFR AF = 0.0148 (611/41376). AF 95% confidence interval is 0.0138. There are 9 homozygotes in GnomAd4. There are 351 alleles in the male GnomAd4 subpopulation. Median coverage is 32. This position passed quality control check.
BS2
High Homozygotes in GnomAd4 at 9 AD,AR gene

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
PKD2NM_000297.4 linkc.305_307dupAGG p.Glu102dup disruptive_inframe_insertion Exon 1 of 15 ENST00000237596.7 NP_000288.1
PKD2NM_001440544.1 linkc.305_307dupAGG p.Glu102dup disruptive_inframe_insertion Exon 1 of 14 NP_001427473.1
PKD2NR_156488.2 linkn.404_406dupAGG non_coding_transcript_exon_variant Exon 1 of 14

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
PKD2ENST00000237596.7 linkc.305_307dupAGG p.Glu102dup disruptive_inframe_insertion Exon 1 of 15 1 NM_000297.4 ENSP00000237596.2
ENSG00000286618ENST00000662475.1 linkn.112+342_112+344dupCTC intron_variant Intron 1 of 2
PKD2ENST00000506727.1 linkn.-211_-210insGAG upstream_gene_variant 4

Frequencies

GnomAD3 genomes
AF:
0.00462
AC:
696
AN:
150526
Hom.:
9
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0148
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00324
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00955
Gnomad NFE
AF:
0.000341
Gnomad OTH
AF:
0.00580
GnomAD2 exomes
AF:
0.00146
AC:
143
AN:
97700
AF XY:
0.00105
show subpopulations
Gnomad AFR exome
AF:
0.0198
Gnomad AMR exome
AF:
0.00174
Gnomad ASJ exome
AF:
0.000149
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.000608
Gnomad OTH exome
AF:
0.00366
GnomAD4 exome
AF:
0.000729
AC:
996
AN:
1366148
Hom.:
2
Cov.:
34
AF XY:
0.000642
AC XY:
433
AN XY:
673950
show subpopulations
African (AFR)
AF:
0.0161
AC:
487
AN:
30168
American (AMR)
AF:
0.00203
AC:
69
AN:
33916
Ashkenazi Jewish (ASJ)
AF:
0.0000405
AC:
1
AN:
24712
East Asian (EAS)
AF:
0.00
AC:
0
AN:
34468
South Asian (SAS)
AF:
0.000117
AC:
9
AN:
77214
European-Finnish (FIN)
AF:
0.0000297
AC:
1
AN:
33702
Middle Eastern (MID)
AF:
0.00624
AC:
35
AN:
5610
European-Non Finnish (NFE)
AF:
0.000248
AC:
265
AN:
1069210
Other (OTH)
AF:
0.00226
AC:
129
AN:
57148
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.455
Heterozygous variant carriers
0
53
106
158
211
264
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
24
48
72
96
120
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.00463
AC:
698
AN:
150616
Hom.:
9
Cov.:
32
AF XY:
0.00477
AC XY:
351
AN XY:
73562
show subpopulations
African (AFR)
AF:
0.0148
AC:
611
AN:
41376
American (AMR)
AF:
0.00323
AC:
49
AN:
15148
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3442
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5134
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4818
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10006
Middle Eastern (MID)
AF:
0.0103
AC:
3
AN:
292
European-Non Finnish (NFE)
AF:
0.000341
AC:
23
AN:
67398
Other (OTH)
AF:
0.00574
AC:
12
AN:
2090
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.499
Heterozygous variant carriers
0
33
67
100
134
167
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
10
20
30
40
50
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.000261
Hom.:
1

ClinVar

Significance: Benign/Likely benign
Submissions summary: Benign:11
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not specified Benign:4
Jul 15, 2014
Eurofins Ntd Llc (ga)
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Mar 27, 2025
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Nov 09, 2017
Genetic Services Laboratory, University of Chicago
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Apr 26, 2017
Athena Diagnostics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

not provided Benign:3
Sep 01, 2024
CeGaT Center for Human Genetics Tuebingen
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

PKD2: BS1

Oct 02, 2020
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is associated with the following publications: (PMID: 20950398, 17574468, 22863349, 21719175, 22508176)

Department of Pathology and Laboratory Medicine, Sinai Health System
Significance:Likely benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

The PKD2 p.Glu102dup variant was identified in 2 of 1564 proband chromosomes (frequency: 0.001) from French, British, and North America individuals or families with ADPKD (Audrezet 2012, Garcia-Gonzalez 2007). There is conflicting evidence in the literature and databases. The variant was identified in a 54 year old male patient with bilateral multicystic kidneys and situs inverus, the duplication segregating with the disease (cystic kidneys) in 1 of the proband’s children and was absent in the 3 unaffected children suggesting that the variant is disease causing (Bataille 2011). The variant was identified in dbSNP (ID: rs547253972) as “NA”, Clinvitae database (classification likely benign and benign), the ClinVar database (classification benign by Invitae and likely benign by Emory Genetics), the ADPKD Mutation Database (classification indeterminate), and COSMIC (1X in a lung carcinoma). This variant was also identified in the 1000 Genomes Project in 37 of 5000 chromosomes (frequency: 0.0074), HAPMAP-AFR in 32 of 1322 chromosomes (frequency: 0.0242), HAPMAP-AMR in 3 of 694 chromosomes (frequency: 0.0043), HAPMAP-EUR in 2 of 1006 chromosomes (frequency: 0.002), and in the Exome Aggregation Consortium database (August 8th 2016) in 928 of 11372 chromosomes (freq. 0.0816) in the following populations: South Asian in 662 of 7216 chromosomes (freq. 0.09), European (Non-Finnish) in 229 of 3242 chromosomes (freq. 0.07), Other in 8 of 128 chromosomes (freq. 0.06), Latino in 8 of 164 chromosomes (freq. 0.05), African in 16 of 442 chromosomes (freq. 0.04), East Asian in 5 of 172 chromosomes (freq. 0.02) but was not seen in the Finnish populations. This high frequency of observations in a control database strongly suggests that the variant is not clinically significant. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) do not predict a difference in splicing. This variant is an in-frame duplication resulting in the addition of a Glutamic acid residue at codon 102; the impact of this alteration on PKD2 protein function is not known. In summary, based on the above information, the clinical significance of this variant cannot be determined with certainty at this time although we would lean towards a more benign role for this variant. This variant is classified as likely benign.

Polycystic kidney disease 2 Benign:2
Apr 21, 2022
Fulgent Genetics, Fulgent Genetics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

May 28, 2019
Mendelics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Autosomal dominant polycystic kidney disease Benign:1
Jan 30, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

PKD2-related disorder Benign:1
Oct 30, 2019
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications).

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
PhyloP100
4.0
Mutation Taster
=75/25
polymorphism

Splicing

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs750077647; hg19: chr4-88929173; COSMIC: COSV52936189; COSMIC: COSV52936189; API